Clinical trial
A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment
NCT05449444 is registered in ClinicalTrials.gov with AB Science as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment
- Lead sponsor
- AB Science
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 1, 2022
- Completion date
- December 31, 2024
- Enrollment
- 72 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.